Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others
he financing was significantly oversubscribed with high demand from both existing and new investors.
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
